Dirk Schadendorf

221.9k total citations · 15 hit papers
982 papers, 46.5k citations indexed

About

Dirk Schadendorf is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Dirk Schadendorf has authored 982 papers receiving a total of 46.5k indexed citations (citations by other indexed papers that have themselves been cited), including 621 papers in Oncology, 498 papers in Molecular Biology and 295 papers in Immunology. Recurrent topics in Dirk Schadendorf's work include Melanoma and MAPK Pathways (305 papers), Cutaneous Melanoma Detection and Management (248 papers) and Immunotherapy and Immune Responses (244 papers). Dirk Schadendorf is often cited by papers focused on Melanoma and MAPK Pathways (305 papers), Cutaneous Melanoma Detection and Management (248 papers) and Immunotherapy and Immune Responses (244 papers). Dirk Schadendorf collaborates with scholars based in Germany, United States and France. Dirk Schadendorf's co-authors include Reinhard Dummer, Caroline Robert, Axel Hauschild, Antje Sucker, Selma Ugurel, Claus Garbe, Jedd D. Wolchok, F. Stephen Hodi, Yuansheng Sun and Frank O. Nestlé and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Dirk Schadendorf

942 papers receiving 45.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 2.4k citations Reinhard Dummer, Dirk Schadendorf et al. profile →
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

2015 1.6k citations Dirk Schadendorf, Caroline Robert et al. Journal of Clinical Oncology profile →
TERT Promoter Mutations in Familial and Sporadic Melanoma

2013 1.3k citations Susanne Horn, Antje Sucker et al. profile →
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

2012 1.1k citations Caroline Robert, Claus Garbe et al. profile →
Melanoma

2018 1.0k citations Dirk Schadendorf, Klaus Griewank et al. profile →
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

2018 1.0k citations Vanna Chiarion‐Sileni, Piotr Rutkowski et al. profile →
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 936 citations Jean‐Jacques Grob, Wolfgang Tilgen et al. Journal of Clinical Oncology profile →
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

2009 934 citations Jedd D. Wolchok, Dirk Schadendorf et al. profile →
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

2017 874 citations Jedd D. Wolchok, Dirk Schadendorf et al. Journal of Clinical Oncology profile →
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

2018 675 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

2013 499 citations Paolo A. Ascierto, Dirk Schadendorf et al. profile →
Melanoma

2015 441 citations Dirk Schadendorf, Claus Garbe et al. profile →
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

2018 392 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
Metabolic heterogeneity confers differences in melanoma metastatic potential

2019 355 citations Dirk Schadendorf et al. profile →
Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review

2018 296 citations Dirk Schadendorf et al. profile →

Peers

Countries citing papers authored by Dirk Schadendorf

Since Specialization

Citations

This map shows the geographic impact of Dirk Schadendorf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Schadendorf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Schadendorf more than expected).

Fields of papers citing papers by Dirk Schadendorf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Schadendorf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Schadendorf. The network helps show where Dirk Schadendorf may publish in the future.

Co-authorship network of co-authors of Dirk Schadendorf

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Schadendorf. A scholar is included among the top collaborators of Dirk Schadendorf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Schadendorf. Dirk Schadendorf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. 2023 ·Journal of Clinical Oncology ·Jason J. Luke, Paolo A. Ascierto, Muhammad Adnan Khattak, Luis de la Cruz‐Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion‐Sileni, John M. Kirkwood, Caroline Robert, Jean‐Jacques Grob, Federica De Galitiis, Dirk Schadendorf, Matteo S. Carlino, (unknown), Mizuho Fukunaga‐Kalabis, Clemens Krepler, Alexander M.M. Eggermont, Georgina V. Long	7
2	Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment 2021 ·Clinical Cancer Research ·(unknown), LeeAnn Ramsay, (unknown), Mathieu Lajoie, Dirk Schadendorf, Tommy Alain, Ian R. Watson	63
3	Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation–Induced DNA Damage and Melanoma Susceptibility 2021 ·Cancer Research ·David de Semir, Vladimir Bezrookove, Mehdi Nosrati, Altaf A. Dar, James R. Miller, Stanley P. L. Leong, Kevin B. Kim, Wilson Liao, Liliana Soroceanu, Sean D. McAllister, Robert J. Debs, Dirk Schadendorf, Sancy A. Leachman, James E. Cleaver, Mohammed Kashani–Sabet	12
4	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response 2021 ·Proceedings of the National Academy of Sciences ·Anastasia Gangaev, Elisa A. Rozeman, Maartje W. Rohaan, Olga I. Isaeva, Daisy Philips, (unknown), Joost H. van den Berg, Antoni Ribas, Dirk Schadendorf, Bastian Schilling, Ton N. Schumacher, Christian U. Blank, John B.A.G. Haanen, Pia Kvistborg	21
5	PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer 2018 ·Proceedings of the National Academy of Sciences ·David de Semir, Vladimir Bezrookove, Mehdi Nosrati, Altaf A. Dar, (unknown), (unknown), (unknown), Meenakshi Venkatasubramanian, James R. Miller, Pierre‐Yves Desprez, Sean D. McAllister, Liliana Soroceanu, Robert J. Debs, Nathan Salomonis, Dirk Schadendorf, James E. Cleaver, Mohammed Kashani–Sabet	16
6	Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients 2018 ·European Journal of Preventive Cardiology ·Matthias Totzeck, Raluca‐Ileana Mincu, Simone M. Mrotzek, Dirk Schadendorf, Tienush Rassaf	67
7	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab 2016 ·Clinical Cancer Research ·Alexander Martens, Kilian Wistuba‐Hamprecht, Jianda Yuan, Michael A. Postow, Phillip Wong, Mariaelena Capone, Gabriele Madonna, Amir Khammari, Bastian Schilling, Antje Sucker, Dirk Schadendorf, Peter Martus, Brigitte Dréno, Paolo A. Ascierto, Jedd D. Wolchok, Graham Pawelec, Claus Garbe, Benjamin Weide	141
8	Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression 2014 ·Clinical Cancer Research ·Antje Sucker, Fang Zhao, Birgit Real, (unknown), Nicola Bielefeld, (unknown), Susanne Horn, Iris Moll, Raffaela Maltaner, Peter A. Horn, Bastian Schilling, Francesco Sabbatino, Volker Lennerz, Matthias Kloor, Soldano Ferrone, Dirk Schadendorf, Christine S. Falk, Klaus Griewank, Annette Paschen	127
9	Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas 2013 ·Clinical Cancer Research ·Klaus Griewank, Henrike Westekemper, Rajmohan Murali, (unknown), Bastian Schilling, Thomas Wiesner, Tobias Schimming, Elisabeth Livingstone, Antje Sucker, Florian Grabellus, Claudia H.D. Metz, Daniela Süßkind, Uwe Hillen, Michael R. Speicher, Scott E. Woodman, (unknown), Dirk Schadendorf	159
10	A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition 2013 ·Cancer Discovery ·Steven R. Whittaker, Jean‐Philippe Theurillat, Eliezer M. Van Allen, Nikhil Wagle, Jessica Hsiao, Glenn S. Cowley, Dirk Schadendorf, David E. Root, Levi A. Garraway	260
11	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition 2012 ·Journal of Clinical Oncology ·Lisa Zimmer, Uwe Hillen, Elisabeth Livingstone, Mario E. Lacouture, Klaus J. Busam, Richard D. Carvajal, Friederike Egberts, Axel Hauschild, Mohammed Kashani–Sabet, Simone M. Goldinger, Reinhard Dummer, Georgina V. Long, Grant A. McArthur, André Scherag, Antje Sucker, Dirk Schadendorf	167
12	Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma 2012 ·Journal of Clinical Oncology ·Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori, Mario Santinami, Wim H.J. Kruit, Jeremy Marsden, Cornelis J.A. Punt, François Salès, Reinhard Dummer, Caroline Robert, Dirk Schadendorf, (unknown), Gaetan de Schaetzen, Alan Spatz, Ulrich Keilholz	190
13	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination 2012 ·Cancer Research ·Erik H.J.G. Aarntzen, I. Jolanda M. de Vries, W. Joost Lesterhuis, Danita H. Schuurhuis, Joannes F.M. Jacobs, Kalijn F. Bol, Gerty Schreibelt, Roel Mus, Johannes H.W. de Wilt, John B.A.G. Haanen, Dirk Schadendorf, Alexandra Croockewit, Willeke A.M. Blokx, Michelle M. van Rossum, William W. Kwok, Gosse J. Adema, Cornelis J.A. Punt, Carl G. Figdor	131
14	Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D 2011 ·Cancer Research ·Anja Heinemann, Fang Zhao, Sonali Pechlivanis, Jürgen Eberle, Alexander Steinle, Sven Diederichs, Dirk Schadendorf, Annette Paschen	167
15	RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors 2011 ·Journal of Clinical Oncology ·Patrick A. Oberholzer, Damien Kee, Piotr Dziunycz, Antje Sucker, Nyam Kamsu-Kom, Robert T. Jones, Christine Roden, (unknown), Kristin Ardlie, Emanuele Palescandolo, Adriano Piris, Laura E. MacConaill, Caroline Robert, Günther F.L. Hofbauer, Grant A. McArthur, Dirk Schadendorf, Levi A. Garraway	298
16	Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth 2009 ·Cancer Research ·Patrick Nasarre, Markus Thomas, Karoline Kruse, Iris Helfrich, (unknown), (unknown), Dirk Schadendorf, Gavin Thurston, Ulrike Fiedler, Hellmut G. Augustin	140
17	Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma 2009 ·Clinical Cancer Research ·Iris Helfrich, Lutz Edler, Antje Sucker, Markus Thomas, Sven Christian, Dirk Schadendorf, Hellmut G. Augustin	152
18	An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma 2008 ·Clinical Cancer Research ·Reinhard Dummer, Axel Hauschild, Juergen C. Becker, Jean‐Jacques Grob, Dirk Schadendorf, Veronica Tebbs, (unknown), Katharina C. Kaehler, (unknown), Ruth Clark, Tze‐Chiang Meng, Mirjana Urosevic	95
19	In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group 2006 ·Clinical Cancer Research ·Selma Ugurel, Dirk Schadendorf, Claudia Pföhler, K. Neuber, A. Thoelke, Jens Ulrich, Axel Hauschild, Konstanze Spieth, Martin Kaatz, Werner Rittgen, Stefan Delorme, Wolfgang Tilgen, Uwe Reinhold	63
20	A Novel Strategy for the Discovery of MHC Class II–Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope 2005 ·Cancer Research ·Till A. Röhn, (unknown), Annette Paschen, Xuan Duc Nguyen, Dirk Schadendorf, Anne B. Vogt, Harald Kropshofer	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact